
A scientist at Gilead Sciences analyzes patient antibody levels at the Gilead laboratory in Foster City, California.
David Paul Morris | Bloomberg | Getty Images
Gilead Sciences said on Monday it had decided to stop a late-stage trial of its intravenous treatment, Veklury, in high-risk non-hospitalized patients with Covid-19.
The company said it no longer believes that developing a multiple-day injection that requires administration in a healthcare setting addresses an unmet need for non-hospitalized patients.
The decision to stop the study is not due to efficacy or safety concerns, Gilead said.
"Stop" - Google News
April 13, 2021 at 05:08AM
https://ift.tt/3mHMYqW
Gilead to stop late-stage study of Covid-19 treatment - CNBC
"Stop" - Google News
https://ift.tt/2KQiYae
https://ift.tt/2WhNuz0
Bagikan Berita Ini
0 Response to "Gilead to stop late-stage study of Covid-19 treatment - CNBC"
Post a Comment